Charles River conducts contract studies in established animal models of multiple sclerosis (MS) to test the efficacy of novel therapeutics. Our animal model platform for MS focuses on induction of experimental allergic encephalomyelitis (EAE) in rats and mice. EAE is induced via injection of an inoculum containing either myelin oligodendrocyte glycoprotein (MOG) or proteolipid protein (PLP). Models include acute, progressive or relapsing-remitting disease course with elements of inflammation and neurodegeneration, components relevant to human MS.